MR 409_product_DataBase

Bioactivity	MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer[1][2][3][4].
Invitro	One week post-myocardial infarction (MI), MR 409 (MR-409) significantly reduces plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo[1].MR 409 (MR-409; 1 μM) suppresses p53 expression in bovine pulmonary arterial endothelial cells (BPAECs)[2].MR 409 (1 μM) induces the activation of JAK2, STAT3 and ERK1/2[2].MR 409 (MR-409; 1 and 5 μM) decreases LPS-induced PGE2 and 8-iso-PGF2α levels, in a dose-dependent manner[3]. MR 409 (1 and 5μM) decreases LPS-induced lactate dehydrogenase (LDH) activity and nitrite production, without showing a dose-dependent effect[3]. MR 409 (1 and 5 μM) decreases LPS-induced gene expression of COX-2, NF-κB and iNOS in colon specimens, without a dose-dependent effect[3]. MR 409 (MR-409) can stimulate endogenous neurogenesis and improve the tMCAO-induced loss of neuroplasticity. MR 409 also enhances the proliferation and inhibits apoptosis of neural stem cells treated with oxygen and glucose deprivation-reperfusion[4]. Western Blot Analysis[2] Cell Line:
Name	MR 409
CAS	1445155-39-4
Shortening	{N-Me}-Y-{D-Ala}-DAIFTNSYR-{Orn}-VL-{Abu}-QLSAR-{Orn}-LLQDI-{Nle}-DR-NHMe
Formula	C153H252N44O43
Molar Mass	3395.91
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.

PeptideDB

MR 409

CAS: 1445155-39-4 F: C153H252N44O43 W: 3395.91